Commercial Biotechnology Industry Review
*Published April 2001
|
INTRODUCTION / SUMMARY
No longer does the biotechnology revolution have to explain its value,
as it did in the beginning. Today the results are tangible¾
with significant product sales, a record number of new products in the
pipeline, and a breathtaking array of basic discoveries having commercial
potential in medicine, agriculture, chemicals and the environment.
Keeping up with all the changing technical and commercial activities is
precisely what this anthology provides. Drawn from the pages of Applied
Genetics News (AGN), coupled with summary analyses of the major fields
of application taken from BCC's industry studies, this anthology details
the sweep of biotechnology activities: in the laboratory, in commercial
production and in the marketplace, revealing who's doing what¾
and why.
Companies are moving from drug discovery and development based in
medicinal chemistry to designing and developing drugs based on information
provided by genomics and related technologies. While gene therapy and
antisense technologies may not enter the market for several more years,
they will change forever the treatment of diseases by actually curing
diseases rather than treating symptoms. Antibody-based drugs, in
particular monoclonal antibody-based products, are on the cusp of
significant commercial growth. New developments in antibody products are
spurred in part by advances in technology that have now surmounted
previous technical barriers to commercialization.
The total market for biotechnology-enabling technologies and selected
"star" products is estimated at nearly $12.5 billion in 2000.
This market is expected to rise at an AAGR (average annual growth rate) of
between 19.3% and 22.8% to as much as $34 billion in 2005.
Enabling technologies–genomics, proteomics, pharmacogenomics, and
bioinformatics—represent the bulk of the market, with sales estimated at
$7.6 billion in 2000. This combined market segment is expected to grow at
an AAGR of 17.7% to cross $17 billion by 2005. The sectors contributing
most to the growth of enabling technologies are pharmacogenomics, which
will have an AAGR exceeding 100% from 2000 to 2005, and microarray assays
or DNA chips, which will have an AAGR approaching 40% during the same
period.
The biotechnology revolution continues to affect nearly every sector of
the economy. It also influences bioprocess technology, along with
supportive reagents and equipment. Today, the importance of biotechnology
to the economy is without doubt. Its practical benefits¾
significant already¾ continue to unfold.
Keeping up with the changing developments relevant to commercial
interests is the purpose of this review, which is based on an anthology of
the 2000 Applied Genetics News newsletter, which takes the pulse of
research, technology, products, applications, patents, industry news,
financial developments and players. It's been said that grasping the
meaning of today's events will shape tomorrow, and our in-depth coverage
of the news provides reporting as well as analysis.
This anthology provides a comprehensive analysis on the biotechnology
sector covering topics on:
 | Bioprocess technology
| Infectious diseases
| Clinical trials
| Neurotechnology
| Diagnostics
| Food
| Agriculture
| Enzymes
| Catalytic RNA
| Cancer
| Genome projects
| Regulatory activity
| Strategic alliances
| Technology transfer
| Energy
| Vaccines |
| | | | | | | | | | | | | | |
DBI00 Commercial Biotechnology Industry Review
Published April 2001
*Data and analysis provided courtesy of
BUSINESS COMMUNICATIONS COMPANY, INC., 25 Van Zant Street, Norwalk, CT
06855, Telephone: (203) 853-4266; ext. 309, Email: publisher@bccresearch.com |
